UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044328
Receipt number R000050630
Scientific Title Screening for ischemic heart disease in HIV-infected patients
Date of disclosure of the study information 2021/05/28
Last modified on 2023/05/02 17:06:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Screening for ischemic heart disease in HIV-infected patients

Acronym

HAIHD

Scientific Title

Screening for ischemic heart disease in HIV-infected patients

Scientific Title:Acronym

HAIHD

Region

Japan


Condition

Condition

HIV
Ischemic Heart Disease

Classification by specialty

Cardiology Infectious disease

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Coronary CT in non-hemophiliac HIV-infected patients to determine the prevalence of ischemic heart disease

Basic objectives2

Others

Basic objectives -Others

Prospective observational study

Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Prevalence of Ischemic Heart Disease in Non-Hemophilic HIV-Infected Patients

Key secondary outcomes

Evaluation for correlation between risk factors for ischemic heart disease and ischemic heart disease in non-hemophilia HIV-infected patients and usefulness of screening test


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Other

Interventions/Control_1

Coronary CT

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Individuals who have given written consent to participate in the research.
(2) Males and females aged 20 years or older at the time of obtaining consent
(3) Those with a positive anti-HIV antibody test result.

Key exclusion criteria

(1) Patients who have been diagnosed with ischemic heart disease
(2) Patients who have been diagnosed with hemophilia
(3) Patients with a history of hypersensitivity to iodine or iodine contrast media
(4) Persons with serious thyroid disease
(5) Patients with severe bronchial asthma
6) Patients with severe cardiac disorders
7) Patients with severe hepatic impairment
8) Patients with severe renal dysfunction
9) Patients with macroglobulinemia
10) Patients with multiple myeloma
11) Patients with tetany
12) Patients with pheochromocytoma or suspected pheochromocytoma
13) Patients of childbearing potential
14) Those who are judged by the principal investigator to be inappropriate for inclusion in the study

Target sample size

70


Research contact person

Name of lead principal investigator

1st name Yukio
Middle name
Last name Hiroi

Organization

National Center for Global Health and Medicine

Division name

Cardiology

Zip code

1628655

Address

1-21-1, Toyama, Shinjuku-ku Tokyo 162-8655, Japan

TEL

03-3202-7181

Email

yhiroi@hosp.ncgm.go.jp


Public contact

Name of contact person

1st name Yukio
Middle name
Last name Hiroi

Organization

National Center for Global Health and Medicine

Division name

Cardiology

Zip code

1628655

Address

1-21-1, Toyama, Shinjuku-ku Tokyo 162-8655, Japan

TEL

03-3202-7181

Homepage URL


Email

yhiroi@hosp.ncgm.go.jp


Sponsor or person

Institute

National Center for Global Health and Medicine

Institute

Department

Personal name



Funding Source

Organization

National Center for Global Health and Medicine

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Division of Medical Research Management, Management and Planning Bureau National Center for Global Health and Medicine

Address

1-21-1, Toyama, Shinjuku-ku Tokyo 162-8655, Japan

Tel

03-3202-7181

Email

rinrijm@hosp.ncgm.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立国際医療研究センター病院


Other administrative information

Date of disclosure of the study information

2021 Year 05 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 04 Month 09 Day

Date of IRB

2021 Year 04 Month 09 Day

Anticipated trial start date

2021 Year 06 Month 01 Day

Last follow-up date

2022 Year 12 Month 31 Day

Date of closure to data entry

2023 Year 01 Month 31 Day

Date trial data considered complete

2023 Year 01 Month 31 Day

Date analysis concluded

2023 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2021 Year 05 Month 26 Day

Last modified on

2023 Year 05 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050630


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name